Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

Cold-Recombinant Influenza A/California/10/78 (H1N1) Virus Vaccine (CR-37) in Seronegative Children: Infectivity and Efficacy against Investigational Challenge

Robert B. Belshe and Lee P. Van Voris
The Journal of Infectious Diseases
Vol. 149, No. 5 (May, 1984), pp. 735-740
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/30131746
Page Count: 6
  • Download ($42.00)
  • Subscribe ($19.50)
  • Cite this Item
Cold-Recombinant Influenza A/California/10/78 (H1N1) Virus Vaccine (CR-37) in Seronegative Children: Infectivity and Efficacy against Investigational Challenge
Preview not available

Abstract

Forty-seven seronegative children were inoculated intranasally with influenza A/California/10/78 (H1N1) cold-recombinant vaccine (CR-37). Doses ranged from $10^{3.2}$ to $10^{7.2} TCID_{50}$ per child. The dose necessary to infect 50% of children (one $HID_{50}$) was $\sim 10^{3.5} TCID_{50}$ . Only two of eight children given $10^{3.2} TCID_{50}$ became infected, and neither shed virus. The majority of children who were given $10^{4.2}$, $10^{5.2}$, $10^{6.2}$, or $10^{7.2} TCID_{50}$ of CR-37 became infected. Twenty-four of 39 children given greater than one $HID_{50}$ of CR-37 shed vaccine virus. Overall, 31 of 39 became infected, as indicated by shedding of virus or antibody response or both. Although virus was shed for up to 12 days postinoculation, shedding of revertant virus was not detected. Six months after primary vaccination 26 children were challenged intranasally with $10^{6.2} TCID_{50}$ of CR-37. Of 21 children previously infected with CR-37, only eight had further antibody increase, and none shed vaccine virus. In contrast, five of five ($P < .05$) children not infected with CR-37 at the time of initial inoculation were infected with the challenge inoculum (as indicated by a fourfold rise in antibody titer) and three of five children shed vaccine virus. Previous infection with CR-37 conferred significant protection from challenge with a high dose of CR-37.

Page Thumbnails

  • Thumbnail: Page 
735
    735
  • Thumbnail: Page 
736
    736
  • Thumbnail: Page 
737
    737
  • Thumbnail: Page 
738
    738
  • Thumbnail: Page 
739
    739
  • Thumbnail: Page 
740
    740